Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9954164 | 0.89 | HCRTR2 (0.62) | HCRTR2HCRTR1 | |
| Hydrochloric Acid SCHEMBL9956387 | 0.89 | HCRTR2 (0.62) | HCRTR2HCRTR1 | |
| Hydrochloric Acid SCHEMBL9954163 | 0.89 | HCRTR2 (0.62) | HCRTR2HCRTR1 | |
| SCHEMBL6923834 | 0.87 | HCRTR2 (0.69) | HCRTR2HCRTR1 | |
| SCHEMBL6901212 | 0.83 | HCRTR1 (0.57) | HCRTR2HCRTR1 | |
| SCHEMBL14850874 | 0.81 | HCRTR2 (0.60) | HCRTR2HCRTR1 | |
| Hydrochloric Acid SCHEMBL14843973 | 0.80 | HCRTR2 (0.59) | HCRTR2HCRTR1 | |
| SCHEMBL1671102 | 0.79 | HCRTR2 (1.00) | HCRTR2HCRTR1 | |
| SCHEMBL11900702 | 0.77 | HCRTR1 (0.61) | HCRTR2HCRTR1 | |
| SCHEMBL1671780 | 0.77 | HCRTR1 (0.61) | HCRTR2HCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680275-B2 | Fused heterocyclic compounds as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2014-03-25 | — | — | US | disclosed |
| US-8680275-B2 | Fused heterocyclic compounds as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2014-03-25 | — | — | US | disclosed |
| US-8680275-B2 | Fused heterocyclic compounds as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2014-03-25 | — | — | US | disclosed |
| EP-2491034-B1 | FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2013-12-18 | — | — | EP | disclosed |
| US-20120202783-A1 | FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS | JANSSEN RESEARCH NV (BE) | 2012-08-09 | — | — | US | disclosed |
| US-20120202783-A1 | FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS | JANSSEN RESEARCH NV (BE) | 2012-08-09 | — | — | US | disclosed |
| WO-2011050200-A1 | FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202783-A1 | FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS | HCRTR2, HCRTR1, OXTR | HCRTR2 1/4885HCRTR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.